Pharmacogenetics to Avoid Adverse Drug Reactions

• Format: eBook
• Language: English
• Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Subjects: Medicine; (es)citalopram; 5-fluorouracil; acute coronary syndrome; adverse drug reactions; adverse events; allele; anti-epileptic drugs (AEDS); antiepileptics; antipsychotic agents; atorvastatin; capecitabine; cardiology; cardiovascular disease; clinical implementation; clopidogrel; colorectal cancer; cutaneous adverse drug reaction; cutaneous adverse drug reactions (CADRs); CYP2C9*3; CYP450 enzymes; cytochrome P-450 enzyme system; direct oral anticoagulants; drug-drug-gene-interaction; drug-drug-interaction; drug-gene-interaction; epistasis; fluoropyrimidine; genetic polymorphism; genetic risk factors; genotype; guidelines; HLA; HLA B; India; n/a; personalised medicine; pharmacogenetics; pharmacogenomics; phenytoin (PHT); platelet reactivity; polymorphism; precision medicine; psychotic disorders; random forest; SCAR; single-nucleotide variants; SLCO1B1; South India; statin; the PharmLines initiative; thymidylate synthase; thymidylate synthase enhancer region; toxicity; upstream stimulatory factor 1
• Online Access: Open Access: DOAB: description of the publication; Open Access: DOAB, download the publication
• Physical Description: 1 online resource (220 p.)
• ISBN: 9783036533438; 9783036533445; books978-3-0365-3343-8
• Access: Open Access

Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.